Lupin gets USFDA’s nod for Prucalopride Tablets

25 Jun 2025 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg, and 2 mg. Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. This product will be manufactured at Lupin’s Goa facility in India.  Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of $184 million in the U.S. (IQVIA MAT April 2025). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2096.45 -16.50 (-0.78%)
29-Dec-2025 12:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1727.80
Dr. Reddys Lab 1262.90
Cipla 1500.50
Zydus Lifesciences 904.60
Lupin 2096.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×